PNC Financial Services Group Inc. Lowers Stake in IQVIA Holdings Inc. $IQV

PNC Financial Services Group Inc. cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 12.3% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 47,960 shares of the medical research company’s stock after selling 6,731 shares during the period. PNC Financial Services Group Inc.’s holdings in IQVIA were worth $8,179,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. J. Safra Sarasin Holding AG grew its stake in IQVIA by 174.3% in the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock valued at $2,891,000 after acquiring an additional 8,151 shares during the period. Franklin Street Advisors Inc. NC acquired a new position in IQVIA during the fourth quarter worth $15,724,000. CWM LLC lifted its holdings in IQVIA by 23.9% during the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after purchasing an additional 10,762 shares in the last quarter. HF Advisory Group LLC grew its position in shares of IQVIA by 1,791.6% in the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock valued at $34,852,000 after purchasing an additional 146,444 shares during the period. Finally, Calamos Advisors LLC increased its stake in shares of IQVIA by 268.1% during the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price target (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Wall Street Zen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a research report on Wednesday, April 8th. HSBC reaffirmed a “buy” rating and issued a $240.00 price target on shares of IQVIA in a research note on Monday, July 6th. Finally, Robert W. Baird increased their price objective on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research note on Wednesday, July 1st. Thirteen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $225.71.

IQVIA Stock Up 0.1%

Shares of NYSE IQV opened at $208.22 on Monday. The stock has a market cap of $34.75 billion, a PE ratio of 25.80, a P/E/G ratio of 1.87 and a beta of 1.20. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $247.04. The company has a 50-day moving average of $188.23 and a 200 day moving average of $187.05.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business’s revenue was up 8.4% on a year-over-year basis. During the same period last year, the company posted $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.